Neoantigen Targeted Therapies Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented by Target Disease Indication (Bone Cancer, Colorectal Cancer, Gynecological Cancer, Non-Small Cell Lung Cancer, Renal Cell Carcinoma), By Neoantigens Type (Off-the-Shelf Neoantigens, Personalized Neoantigens), By Immunotherapy Type (Dendritic Cell Vaccines, DNA / RNA-Based Vaccines, Protein / Peptide-based Vaccines, TIL-Based Therapies), By Route of Administration (Intradermal, Intravenous, Subcutaneous), By Region, and Competition 2018-2028

  • Industry : Healthcare
  • Pages : NA
  • Published Date : NA
Customization Enquiry

Buy Now

Summary

Report Description

 

Forecast Period

2024-2028

Market Size (2022)

USD 1.88 billion

CAGR (2024-2028)

8.34%

Fastest Growing Segment

Off-the-Shelf Neoantigens

Largest Market

North America

 

Market Overview

Global Neoantigen Targeted Therapies Market has valued at USD 1.88 billion in 2022 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 8.34% through 2028. Neoantigen Targeted Therapies are a cutting-edge approach in cancer treatment that harnesses the power of the immune system to specifically recognize and attack cancer cells. These therapies are designed to target neoantigens, which are unique protein fragments found on the surface of cancer cells because of mutations in the tumor's DNA. Neoantigens are distinct from normal, healthy cell proteins, making them ideal targets for immune recognition and attack. Neoantigen therapies are highly personalized. Once neoantigens are identified, the patient's immune system is trained to recognize these specific neoantigens as foreign invaders. This often involves creating a customized vaccine or adoptive cell therapy tailored to the patient's unique neoantigen profile. Neoantigen therapies can be used in combination with checkpoint inhibitors, another type of immunotherapy. Checkpoint inhibitors release the brakes on the immune system, allowing it to mount a stronger response against cancer cells, including those targeted by neoantigens.

The growing availability and affordability of genomic sequencing technologies have enabled the identification of neoantigens more accurately and quickly, facilitating the development of personalized therapies. Regulatory agencies like the FDA and EMA have shown willingness to support the development and approval of neoantigen therapies, streamlining the path to market for these treatments. Patients and healthcare providers are increasingly seeking precision therapies that specifically target cancer cells. Neoantigen therapies offer the potential for more effective and less toxic treatments. Researchers are exploring the synergistic effects of combining neoantigen therapies with other treatment modalities, such as chemotherapy and radiation therapy, to enhance treatment outcomes. The aging population is at higher risk of developing cancer. As the global population ages, the demand for innovative cancer treatments, including neoantigen therapies, is expected to rise.

Key Market Drivers

Advancements in Genomic Testing

Next-generation sequencing technologies have revolutionized the field of genomics. NGS allows for the rapid and cost-effective sequencing of large stretches of DNA. It has enabled the sequencing of entire genomes, transcriptomes, and epigenomes with unprecedented speed and affordability. High-throughput sequencing platforms can simultaneously process numerous DNA or RNA samples, allowing for large-scale studies and population-scale genomic research. This capability has accelerated the discovery of genetic variants associated with diseases and traits. Traditional short-read sequencing methods have limitations in resolving complex genomic regions. Long-read sequencing technologies, like Pacific Biosciences (PacBio) and Oxford Nanopore, can generate much longer sequencing reads, aiding in the assembly of complete genomes and the identification of structural variations. Single-cell sequencing technologies enable the analysis of individual cells within a tissue or organism. This approach provides insights into cellular heterogeneity, cell types, and gene expression at a single-cell resolution, advancing our understanding of complex biological systems. Genomic sequencing has been instrumental in cancer research and precision oncology. It allows for the identification of driver mutations, assessment of tumor heterogeneity, and the development of targeted therapies tailored to a patient's genetic profile.

Genome editing technologies, such as CRISPR-Cas9, combined with genomic sequencing, enable researchers to understand gene function by selectively modifying genes and observing their effects on cellular processes. Genomic sequencing has expanded beyond the study of individual organisms to the analysis of entire microbial communities (metagenomics). This has implications for microbiome research, ecology, and infectious disease studies. Genomic sequencing has been applied to epigenetic research, allowing for the mapping of DNA methylation patterns, histone modifications, and chromatin accessibility. This provides insights into gene regulation and cell identity. Genomic sequencing is increasingly used in clinical settings for diagnosing genetic disorders, identifying disease-causing mutations, and guiding treatment decisions. It has also enabled non-invasive prenatal testing (NIPT) and pharmacogenomics. Advances in genomic sequencing have made it more accessible to the public, leading to the rise of direct-to-consumer genetic testing services. Individuals can now obtain insights into their ancestry, traits, and health risks based on their genetic data. This factor will help in the development of the Global Neoantigen Targeted Therapies Market.

Increasing Patient Demand for Targeted Therapies

Patients increasingly seek personalized treatment options that specifically target the unique characteristics of their disease. Neoantigen-targeted therapies offer a highly personalized approach, as they are tailored to the genetic and immunological profile of each patient's cancer. Patients often prefer treatments that minimize side effects and improve their overall quality of life. Neoantigen therapies aim to spare healthy tissues while selectively targeting cancer cells, potentially reducing adverse effects associated with traditional treatments like chemotherapy. Patients and their families are becoming more informed about the latest advancements in cancer treatment, including targeted therapies like neoantigen-based treatments. This awareness drives discussions with healthcare providers and influences treatment decisions. Advances in genomic sequencing have empowered patients by providing insights into their own genetic makeup and the genetic drivers of their cancer. This information encourages patients to explore treatment options that align with their genomic profile.

Patient advocacy groups and organizations play a crucial role in raising awareness about the availability and benefits of targeted therapies. They provide support, information, and resources to patients and their families. Many patients are willing to participate in clinical trials, including those involving neoantigen-targeted therapies, as they see these trials as opportunities to access cutting-edge treatments not yet widely available. Positive outcomes and success stories from patients who have benefited from targeted therapies, including neoantigen therapies, further fuel demand. Patients often share their experiences, inspiring others to explore similar treatment options. Neoantigen therapies, with their potential for reduced toxicity, are attractive to patients who wish to avoid the harsh side effects associated with traditional cancer treatments. Patients facing advanced or hard-to-treat cancers may view neoantigen therapies as a source of hope and a potential lifeline. This hope can drive their interest in exploring these innovative treatment options. Oncologists and healthcare providers who are knowledgeable about neoantigen therapies and their potential benefits are more likely to discuss these options with patients, increasing patient awareness and demand. This factor will pace up the demand of the Global Neoantigen Targeted Therapies Market.

Rising Aging Population

As individuals age, their risk of developing cancer typically increases. Cancer is more prevalent among older adults, and many cancers are diagnosed in individuals over the age of 65. This demographic trend creates a larger patient pool for cancer therapies, including Neoantigen Targeted Therapies. Cancers that affect older individuals can be more complex and challenging to treat. Aging-related changes in the immune system and a higher likelihood of comorbidities can make standard treatments less effective. Neoantigen therapies offer innovative approaches that may be more tailored to the unique characteristics of these cancers. Older adults may have lower tolerance for the side effects of traditional cancer treatments like chemotherapy. Neoantigen therapies, with their potential for reduced toxicity, are often more appealing to this patient group. Advances in healthcare have led to longer life expectancy, and older individuals are more likely to pursue treatments that offer the potential for extended survival and improved quality of life. Neoantigen therapies are designed to target cancer cells while sparing healthy tissues, potentially providing these benefits. The concept of precision medicine, which includes tailoring treatments to individual patients, aligns with the healthcare needs and preferences of older adults. Neoantigen therapies are a prime example of personalized medicine, as they are customized to a patient's unique cancer profile.

Older patients and their families are increasingly proactive in seeking information about cancer treatment options. Patient advocacy groups and educational resources play a role in raising awareness about the availability and benefits of Neoantigen Targeted Therapies. Older adults are willing to participate in clinical trials, including those involving Neoantigen therapies, to access cutting-edge treatments. Their involvement in research contributes to the development and validation of these therapies. Many countries are grappling with the economic impact of an aging population's healthcare needs. Neoantigen therapies, by potentially offering more effective and cost-efficient treatments, may be viewed favorably by healthcare systems and payers. Aging is associated with an increased prevalence of chronic conditions. Neoantigen therapies, by targeting the root cause of cancer, offer the potential to address the underlying condition and its complications. As the aging population continues to grow, it expands the overall market for cancer therapies, creating opportunities for pharmaceutical companies and researchers to develop and market Neoantigen Targeted Therapies. This factor will accelerate the demand of the Global Neoantigen Targeted Therapies Market.


Download Free Sample Report

Key Market Challenges

Identification of Relevant Neoantigens

Tumors are often genetically heterogeneous, meaning they contain a mix of different cell types with various mutations. Identifying the specific neoantigens that are present across all tumor cells can be challenging. Neoantigen prediction relies on computational algorithms to predict potential neoantigens based on DNA sequencing data. These algorithms are continually improving, but false positives and false negatives are still common, leading to uncertainty in selecting the most relevant neoantigens. Predicted neoantigens must be experimentally validated to confirm their presentation on cancer cells and their immunogenicity. This validation process can be time-consuming and resource intensive. Each patient's tumor has a unique set of neoantigens, and these can vary greatly from one patient to another. Identifying relevant neoantigens requires a personalized approach for each patient, which can be logistically challenging. Some neoantigens may be present at very low frequencies within a tumor, making them difficult to detect and target effectively. Tumors can evolve over time, leading to changes in their neoantigen landscape. This requires ongoing monitoring and adaptation of neoantigen-targeted therapies. Cancer cells may develop mechanisms to evade the immune system, including downregulating the presentation of neoantigens. This immune evasion can hinder the effectiveness of neoantigen-targeted therapies.

Clinical Trial Complexity

Identifying patients with the appropriate neoantigen profiles for specific therapies is a key challenge. Neoantigen therapies are highly personalized, and patient selection is critical for treatment efficacy. Each patient's neoantigen profile is unique, requiring the customization of treatment for individual participants. This necessitates specialized manufacturing processes for each patient. Designing clinical trials for neoantigen therapies often involves complex protocols that include genomic sequencing, neoantigen prediction, and personalized vaccine or T-cell therapy production. These processes must be seamlessly integrated into the trial design. Managing the logistics of personalized neoantigen therapies, including sample collection, sequencing, manufacturing, and administration, can be challenging and resource intensive. Accurate prediction of neoantigens relies on sophisticated bioinformatics tools. Ensuring the reliability and consistency of these tools across multiple trial sites is essential. Validating the predicted neoantigens and ensuring the quality and consistency of vaccine or T-cell production are critical aspects of trial conduct. Quality control measures must be rigorous. Regulatory agencies often require substantial data on the safety and efficacy of neoantigen therapies, making the regulatory pathway complex and time-consuming. Obtaining informed consent from patients for the various stages of neoantigen-based trials, including genomic sequencing and treatment, requires careful communication and adherence to ethical standards.

Key Market Trends

Immunotherapy Dominance

Immunotherapy has gained prominence as a leading approach in cancer treatment. It harnesses the body's immune system to target and destroy cancer cells. Neoantigen-targeted therapies are a subset of immunotherapy that focuses on training the immune system to recognize and attack cancer-specific neoantigens. Immunotherapy, including neoantigen-targeted therapies, aligns with the principles of precision medicine. These therapies are tailored to the individual genetic and immunological profiles of each patient, aiming to maximize treatment efficacy while minimizing side effects. Neoantigen-targeted therapies often complement the use of checkpoint inhibitors, another class of immunotherapies. Checkpoint inhibitors release the brakes on the immune system, allowing it to attack cancer cells more effectively. Neoantigens can serve as specific targets for the immune system to recognize in combination with checkpoint inhibitors. Neoantigen-targeted therapies aim to enhance the immune system's response against cancer cells by targeting neoantigens, which are unique to the tumor. This can lead to a more focused and potent immune response compared to traditional treatments. Positive outcomes and clinical successes in immunotherapy trials, including neoantigen therapies, have fueled interest and investment in this field. Patients who have experienced durable responses are advocating for and raising awareness of these treatments. The pharmaceutical and biotechnology industries have invested heavily in the research and development of immunotherapies, including neoantigen-based approaches. This investment has led to a growing pipeline of potential therapies.

Segmental Insights

Target Disease Indication Insights

In 2022, the Global Neoantigen Targeted Therapies Market was dominated by the Colorectal Cancer segment and is predicted to continue expanding over the coming years. Colorectal cancer is one of the most common types of cancer globally. Its high incidence rates result in a substantial patient population, making it an attractive target for therapeutic interventions, including neoantigen-based therapies. Colorectal cancer can be aggressive and challenging to treat, particularly in advanced stages. Patients with advanced colorectal cancer often have limited treatment options, which creates a strong demand for innovative therapies like neoantigen-targeted treatments. It is known for having an immunogenic tumour microenvironment. This means that it tends to elicit immune responses, making it a promising candidate for immunotherapies like neoantigen-targeted therapies.

Neoantigens Type Insights

In 2022, the Global Neoantigen Targeted Therapies Market largest share was held by Off-the-Shelf Neoantigens segment and is predicted to continue expanding over the coming years.  Off-the-shelf neoantigen therapies are pre-manufactured and readily available for use, eliminating the need for the time-consuming and expensive process of personalized neoantigen identification and production. This accessibility and convenience make them a practical choice for a broader patient population. Personalized neoantigen therapies require the identification of specific neoantigens for each patient, limiting their application to a subset of patients. In contrast, off-the-shelf neoantigens can be used in a more extensive range of patients, including those who may not have identified neoantigens suitable for personalized therapies. Developing personalized neoantigen therapies can be costly and time-intensive due to the need for individualized manufacturing processes. Off-the-shelf therapies are often more cost-effective because they can be produced in larger batches, reducing production costs.

Immunotherapy Type Insights

In 2022, the Global Neoantigen Targeted Therapies Market largest share was held by Protein / Peptide-based Vaccines segment with a revenue of around and is predicted to continue expanding over the coming years. Protein and peptide-based vaccines are designed to target specific neoantigens present on cancer cells while minimizing off-target effects. They are known for their safety profile and high specificity, making them attractive options for cancer immunotherapy. Protein and peptide-based vaccines can be tailored to each patient's unique neoantigen profile. This personalized approach can potentially enhance their effectiveness in treating a wide range of cancer types. Many protein and peptide-based vaccines are designed to be highly immunogenic, stimulating a robust immune response against cancer cells. This immunogenicity is critical for the therapeutic success of neoantigen vaccines.

Route of Administration Insights

In 2022, the Global Neoantigen Targeted Therapies Market largest share was held by Intravenous segment and is predicted to continue expanding over the coming years. Intravenous administration allows for precise and consistent dosing of neoantigen therapies. This route ensures that the therapy is directly delivered into the bloodstream, which can lead to more predictable and controlled systemic effects. Neoantigen therapies administered intravenously quickly distribute throughout the body, reaching target cells and tissues efficiently. This is particularly important for systemic diseases like cancer, where cancer cells may be present at multiple sites. Many neoantigen therapies, such as monoclonal antibodies and adoptive T-cell therapies, are large molecules that may not be effectively absorbed through other routes, like oral administration. Intravenous administration bypasses issues related to absorption and bioavailability.


Download Free Sample Report

Regional Insights

The North America region has established itself as the leader in the Global Neoantigen Targeted Therapies Market in 2022. North America, particularly the United States, boasts a highly advanced and well-developed healthcare infrastructure. This includes world-renowned research institutions, top-tier medical centers, and a robust biotechnology and pharmaceutical industry, all of which contribute to the development and adoption of cutting-edge therapies like neoantigen targeted therapies. The region is a global hub for biomedical research and innovation. North American researchers and institutions are at the forefront of scientific discoveries related to cancer biology, immunology, and genomics, which are critical fields for the development of neoantigen therapies. North America attracts significant investment in the biotechnology and pharmaceutical sectors. The availability of venture capital, private equity, and public funding sources provides the financial support needed for research and development efforts.

Recent Developments

  • In March 2022, BioNTech SE has recently announced an expansion of its strategic collaboration with Regeneron. This expansion aims to advance the development of BNT116, BioNTech's FixVac candidate, in combination with Libtayo, a PD-1 inhibitor, for the treatment of advanced non-small cell lung cancer (NSCLC). The collaboration involves joint clinical trials designed to assess the effectiveness of this combination therapy in various patient populations with advanced NSCLC. Lung cancer is one of the most diagnosed malignancies globally and remains a leading cause of cancer-related mortality. Among lung cancer cases, NSCLC constitutes approximately 85% of all instances.  According to the agreement, both BioNTech and Regeneron will evenly split the expenses related to the trials' development. Furthermore, BioNTech intends to independently initiate and support a Phase 1 clinical trial known as LuCa-MERIT-1, which will assess the combined use of BNT116 and Libtayo in additional subpopulations affected by NSCLC.
  • In January 2020, BioNTech and Neon Therapeutics, Inc. have formally agreed to merge, with BioNTech acquiring Neon in an all-stock deal valued at around $67.0 million. Neon is a biotech firm specializing in the development of innovative T cell therapies based on neoantigens. Following the completion of the transaction, Neon will continue to operate as a subsidiary of BioNTech, a global biotech company focused on patient-specific immunotherapies for cancer treatment and other critical illnesses. This merger unites two organizations that share a common culture of advancing translational science and a joint vision for the future of cancer immunotherapy. Neon possesses extensive expertise in the development of neoantigen therapies, encompassing both vaccine and T-cell capabilities. Among Neon's most advanced initiatives is NEO-PTC-01, a personalized neoantigen-focused T-cell therapy candidate designed to target the most therapeutically significant neoantigens derived from each patient's tumor. Additionally, Neon is actively progressing a precision T-cell therapy program that specifically targets shared neoantigens within genetically defined patient groups. Notably, NEO-STC-01, a T-cell therapy candidate, leads this approach by targeting shared RAS neoantigens. Furthermore, Neon has curated collections of high-quality T-cell receptors (TCRs) aimed at various shared neoantigens present across common human leukocyte antigen (HLA) types.

Key Market Players

  • BioNtech SE
  • Gritstone Bio, Inc.
  • Genocea Biosciences Inc.
  • Moderna Inc
  • Agenus Inc.
  • Immatics NV
  • Advaxis Inc
  • Precision Biologics
  • Gilead Sciences, Inc.
  • Cellular Biomedicine Group Inc.           
  • Achillies Therapeutics Plc.
  • Merck & Co Inc 

By Target Disease Indication

By Neoantigens Test

By Immunotherapy Type

By Route of Administration

By Region
  • Bone Cancer
  • Colorectal Cancer
  • Gynecological Cancer
  • Non-Small Cell Lung Cancer
  • Renal Cell Carcinoma
  • Off-the-Shelf Neoantigens
  • Personalized Neoantigens
  • Off-the-Shelf Neoantigens
  • Personalized Neoantigens

 
  • Off-the-Shelf Neoantigens
  • Personalized Neoantigens

 
  • North America
  • Europe
  • Asia Pacific
  • South America
  • Middle East & Africa

Report Scope:

In this report, the Global Neoantigen Targeted Therapies Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

  • Neoantigen Targeted Therapies Market, By Target Disease Indication:

o   Bone Cancer

o   Colorectal Cancer

o   Gynecological Cancer

o   Non-Small Cell Lung Cancer

o   Renal Cell Carcinoma

  • Neoantigen Targeted Therapies Market, By Neoantigens Type:

o   Off-the-Shelf Neoantigens

o   Personalized Neoantigens

  • Neoantigen Targeted Therapies Market, By Immunotherapy Type:

o   Dendritic Cell Vaccines

o   DNA / RNA-Based Vaccines

o   Protein / Peptide-based Vaccines

o   TIL-Based Therapies

  • Neoantigen Targeted Therapies Market, By Route of Administration:

o   Intradermal

o   Intravenous

o   Subcutaneous

  • Global Neoantigen Targeted Therapies Market, By region:

o   North America

§  United States

§  Canada

§  Mexico

o   Asia-Pacific

§  China

§  India

§  South Korea

§  Australia

§  Japan

o   Europe

§  Germany

§  France

§  United Kingdom

§  Spain

§  Italy

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Neoantigen Targeted Therapies Market.

Available Customizations:

Global Neoantigen Targeted Therapies Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Global Neoantigen Targeted Therapies Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1.    Product Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.     Markets Covered

1.2.2.     Years Considered for Study

1.2.3.     Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the Study

2.2.  Baseline Methodology

2.3.  Key Industry Partners

2.4.  Major Association and Secondary Applications

2.5.  Forecasting Methodology

2.6.  Data Triangulation & Validation

2.7.  Assumptions and Limitations

3.    Executive Summary

3.1.  Overview of the Market

3.2.  Overview of Key Market Segmentations

3.3.  Overview of Key Market Players

3.4.  Overview of Key Regions/Countries

3.5.  Overview of Market Drivers, Challenges, Trends

4.    Impact of COVID-19 on Global Neoantigen Targeted Therapies Market

5.    Voice of Customer

6.    Global Neoantigen Targeted Therapies Market Outlook

6.1.  Market Size & Forecast

6.1.1.     By Value                      

6.2.  Market Share & Forecast

6.2.1.     By Target Disease Indication (Bone Cancer, Colorectal Cancer, Gynecological Cancer, Non-Small Cell Lung Cancer, Renal Cell Carcinoma)

6.2.2.     By Neoantigens Type (Off-the-Shelf Neoantigens, Personalized Neoantigens)

6.2.3.     By Route of Administration (Intradermal, Intravenous, Subcutaneous)

6.2.4.     By Immunotherapy Type (Dendritic Cell Vaccines, DNA / RNA-Based Vaccines, Protein / Peptide-based Vaccines, TIL-Based Therapies)

6.2.5.     By Region

6.2.6.     By Company (2022)

6.3.  Market Map

7.    Asia Pacific Neoantigen Targeted Therapies Market Outlook

7.1.  Market Size & Forecast

7.1.1.     By Value

7.2.  Market Share & Forecast

7.2.1.     By Target Disease Indication

7.2.2.     By Neoantigens Type

7.2.3.     By Route of Administration

7.2.4.     By Immunotherapy Type

7.2.5.     By Country

7.3.  Asia Pacific: Country Analysis

7.3.1.     China Neoantigen Targeted Therapies Market Outlook

7.3.1.1.         Market Size & Forecast

7.3.1.1.1.             By Value

7.3.1.2.         Market Share & Forecast

7.3.1.2.1.             By Target Disease Indication

7.3.1.2.2.             By Neoantigens Type

7.3.1.2.3.             By Route of Administration

7.3.1.2.4.             By Immunotherapy Type

7.3.2.     India Neoantigen Targeted Therapies Market Outlook

7.3.2.1.         Market Size & Forecast

7.3.2.1.1.             By Value

7.3.2.2.         Market Share & Forecast

7.3.2.2.1.             By Target Disease Indication

7.3.2.2.2.             By Neoantigens Type

7.3.2.2.3.             By Route of Administration

7.3.2.2.4.             By Immunotherapy Type

7.3.3.     Australia Neoantigen Targeted Therapies Market Outlook

7.3.3.1.         Market Size & Forecast

7.3.3.1.1.             By Value

7.3.3.2.         Market Share & Forecast

7.3.3.2.1.             By Target Disease Indication

7.3.3.2.2.             By Neoantigens Type

7.3.3.2.3.             By Route of Administration

7.3.3.2.4.             By Immunotherapy Type

7.3.4.     Japan Neoantigen Targeted Therapies Market Outlook

7.3.4.1.         Market Size & Forecast

7.3.4.1.1.             By Value

7.3.4.2.         Market Share & Forecast

7.3.4.2.1.             By Target Disease Indication

7.3.4.2.2.             By Neoantigens Type

7.3.4.2.3.             By Route of Administration

7.3.4.2.4.             By Immunotherapy Type

7.3.5.     South Korea Neoantigen Targeted Therapies Market Outlook

7.3.5.1.         Market Size & Forecast

7.3.5.1.1.             By Value

7.3.5.2.         Market Share & Forecast

7.3.5.2.1.             By Target Disease Indication

7.3.5.2.2.             By Neoantigens Type

7.3.5.2.3.             By Route of Administration

7.3.5.2.4.             By Immunotherapy Type

8.    Europe Neoantigen Targeted Therapies Market Outlook

8.1.  Market Size & Forecast

8.1.1.     By Value

8.2.  Market Share & Forecast

8.2.1.     By Target Disease Indication

8.2.2.     By Neoantigens Type

8.2.3.     By Route of Administration

8.2.4.     By Immunotherapy Type

8.2.5.     By Country

8.3.  Europe: Country Analysis

8.3.1.     France Neoantigen Targeted Therapies Market Outlook

8.3.1.1.         Market Size & Forecast

8.3.1.1.1.             By Value

8.3.1.2.         Market Share & Forecast

8.3.1.2.1.             By Target Disease Indication

8.3.1.2.2.             By Neoantigens Type

8.3.1.2.3.             By Route of Administration

8.3.1.2.4.             By Immunotherapy Type

8.3.2.     Germany Neoantigen Targeted Therapies Market Outlook

8.3.2.1.         Market Size & Forecast

8.3.2.1.1.             By Value

8.3.2.2.         Market Share & Forecast

8.3.2.2.1.             By Target Disease Indication

8.3.2.2.2.             By Neoantigens Type

8.3.2.2.3.             By Route of Administration

8.3.2.2.4.             By Immunotherapy Type

8.3.3.     Spain Neoantigen Targeted Therapies Market Outlook

8.3.3.1.         Market Size & Forecast

8.3.3.1.1.             By Value

8.3.3.2.         Market Share & Forecast

8.3.3.2.1.             By Target Disease Indication

8.3.3.2.2.             By Neoantigens Type

8.3.3.2.3.             By Route of Administration

8.3.3.2.4.             By Immunotherapy Type

8.3.4.     Italy Neoantigen Targeted Therapies Market Outlook

8.3.4.1.         Market Size & Forecast

8.3.4.1.1.             By Value

8.3.4.2.         Market Share & Forecast

8.3.4.2.1.             By Target Disease Indication

8.3.4.2.2.             By Neoantigens Type

8.3.4.2.3.             By Route of Administration

8.3.4.2.4.             By Immunotherapy Type

8.3.5.     United Kingdom Neoantigen Targeted Therapies Market Outlook

8.3.5.1.         Market Size & Forecast

8.3.5.1.1.             By Value

8.3.5.2.         Market Share & Forecast

8.3.5.2.1.             By Target Disease Indication

8.3.5.2.2.             By Neoantigens Type

8.3.5.2.3.             By Route of Administration

8.3.5.2.4.             By Immunotherapy Type

9.    North America Neoantigen Targeted Therapies Market Outlook

9.1.  Market Size & Forecast

9.1.1.     By Value

9.2.  Market Share & Forecast

9.2.1.     By Target Disease Indication

9.2.2.     By Neoantigens Type

9.2.3.     By Route of Administration

9.2.4.     By Immunotherapy Type

9.2.5.     By Country

9.3.  North America: Country Analysis

9.3.1.     United States Neoantigen Targeted Therapies Market Outlook

9.3.1.1.         Market Size & Forecast

9.3.1.1.1.             By Value

9.3.1.2.         Market Share & Forecast

9.3.1.2.1.             By Target Disease Indication

9.3.1.2.2.             By Neoantigens Type

9.3.1.2.3.             By Route of Administration

9.3.1.2.4.             By Immunotherapy Type

9.3.2.     Mexico Neoantigen Targeted Therapies Market Outlook

9.3.2.1.         Market Size & Forecast

9.3.2.1.1.             By Value

9.3.2.2.         Market Share & Forecast

9.3.2.2.1.             By Target Disease Indication

9.3.2.2.2.             By Neoantigens Type

9.3.2.2.3.             By Route of Administration

9.3.2.2.4.             By Immunotherapy Type

9.3.3.     Canada Neoantigen Targeted Therapies Market Outlook

9.3.3.1.         Market Size & Forecast

9.3.3.1.1.             By Value

9.3.3.2.         Market Share & Forecast

9.3.3.2.1.             By Target Disease Indication

9.3.3.2.2.             By Neoantigens Type

9.3.3.2.3.             By Route of Administration

9.3.3.2.4.             By Immunotherapy Type

10.  South America Neoantigen Targeted Therapies Market Outlook

10.1.              Market Size & Forecast

10.1.1.  By Value

10.2.              Market Share & Forecast

10.2.1.  By Target Disease Indication

10.2.2.  By Neoantigens Type

10.2.3.  By Route of Administration

10.2.4.  By Immunotherapy Type

10.2.5.  By Country

10.3.              South America: Country Analysis

10.3.1.  Brazil Neoantigen Targeted Therapies Market Outlook

10.3.1.1.      Market Size & Forecast

10.3.1.1.1.           By Value

10.3.1.2.      Market Share & Forecast

10.3.1.2.1.           By Target Disease Indication

10.3.1.2.2.           By Neoantigens Type

10.3.1.2.3.           By Route of Administration

10.3.1.2.4.           By Immunotherapy Type

10.3.2.  Argentina Neoantigen Targeted Therapies Market Outlook

10.3.2.1.      Market Size & Forecast

10.3.2.1.1.           By Value

10.3.2.2.      Market Share & Forecast

10.3.2.2.1.           By Target Disease Indication

10.3.2.2.2.           By Neoantigens Type

10.3.2.2.3.           By Route of Administration

10.3.2.2.4.           By Immunotherapy Type

10.3.3.  Colombia Neoantigen Targeted Therapies Market Outlook

10.3.3.1.      Market Size & Forecast

10.3.3.1.1.           By Value

10.3.3.2.      Market Share & Forecast

10.3.3.2.1.           By Target Disease Indication

10.3.3.2.2.           By Neoantigens Type

10.3.3.2.3.           By Route of Administration

10.3.3.2.4.           By Immunotherapy Type

11.  Middle East and Africa Neoantigen Targeted Therapies Market Outlook

11.1.              Market Size & Forecast

11.1.1.  By Value

11.2.              Market Share & Forecast

11.2.1.  By Target Disease Indication

11.2.2.  By Neoantigens Type

11.2.3.  By Route of Administration

11.2.4.  By Immunotherapy Type

11.2.5.  By Country

11.3.              MEA: Country Analysis

11.3.1.  South Africa Neoantigen Targeted Therapies Market Outlook

11.3.1.1.      Market Size & Forecast

11.3.1.1.1.           By Value

11.3.1.2.      Market Share & Forecast

11.3.1.2.1.           By Target Disease Indication

11.3.1.2.2.           By Neoantigens Type

11.3.1.2.3.           By Route of Administration

11.3.1.2.4.           By Immunotherapy Type

11.3.2.  Saudi Arabia Neoantigen Targeted Therapies Market Outlook

11.3.2.1.      Market Size & Forecast

11.3.2.1.1.           By Value

11.3.2.2.      Market Share & Forecast

11.3.2.2.1.           By Target Disease Indication

11.3.2.2.2.           By Neoantigens Type

11.3.2.2.3.           By Route of Administration

11.3.2.2.4.           By Immunotherapy Type

11.3.3.  UAE Neoantigen Targeted Therapies Market Outlook

11.3.3.1.      Market Size & Forecast

11.3.3.1.1.           By Value

11.3.3.2.      Market Share & Forecast

11.3.3.2.1.           By Target Disease Indication

11.3.3.2.2.           By Neoantigens Type

11.3.3.2.3.           By Route of Administration

11.3.3.2.4.           By Immunotherapy Type

12.  Market Dynamics

12.1.              Drivers

12.2.              Challenges

13.  Market Trends & Developments

13.1.              Recent Developments

13.2.              Product Launches

13.3.              Mergers & Acquisitions

14.  Global Neoantigen Targeted Therapies Market: SWOT Analysis

15.  Porter’s Five Forces Analysis

15.1.              Competition in the Industry

15.2.              Potential of New Entrants

15.3.              Power of Suppliers

15.4.              Power of Customers

15.5.              Threat of Substitute Product

16.  PESTLE Analysis

17.  Competitive Landscape

17.1.              BioNtech SE

17.1.1.  Business Overview

17.1.2.  Company Snapshot

17.1.3.  Products & Services

17.1.4.  Financials (In case of listed companies)

17.1.5.  Recent Developments

17.2.              Gritstone Bio, Inc.

17.3.              Genocea Biosciences Inc

17.4.              Moderna Inc.

17.5.              Agenus Inc.

17.6.              Immatics N.V.

17.7.              Advaxis Inc.

17.8.              Precision Biologics

17.9.              Gilead Sciences, Inc.

17.10.            Cellular Biomedicine Group, Inc.

17.11.            Achillies Therapeutics Plc.

17.12.            Merck & Co, Inc.

18.  Strategic Recommendations

19.  About Us & Disclaimer

Figures and Tables

Frequently asked questions

down-arrow

The market size of the Global Neoantigen Targeted Therapies Market was estimated to be USD 1.88 billion in 2022.

down-arrow

Agenus Inc., Moderna Inc Henry Shein Inc. are some of the key players operating in the Global Neoantigen Targeted Therapies Market.

down-arrow

Identifying neoantigens that are specific to a patient's tumor can be challenging.

down-arrow

Immunotherapies, including neoantigen-targeted therapies, have continued to gain prominence in cancer treatment.

Related Reports

profile

Sakshi Bajaal

Business Consultant
Press Release

Global Neoantigen Targeted Therapies Market to grow at a CAGR of 8.34%.

Oct, 2023

Increasing ophthalmic surgeries and initiatives taken by the government are the major drivers for the Global Neoantigen Targeted Therapies Market.

Why Choose Us